{"title":"健康志愿者口服标准布洛芬、布洛芬钠或布洛芬酸合并poloxamer后布洛芬的生物利用度。","authors":"Peter M Dewland, Sandie Reader, Phillip Berry","doi":"10.1186/1472-6904-9-19","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to compare the pharmacokinetic properties of sodium ibuprofen and ibuprofen acid incorporating poloxamer with standard ibuprofen acid tablets.</p><p><strong>Methods: </strong>Twenty-two healthy volunteers were enrolled into this randomised, single-dose, 3-way crossover, open-label, single-centre, pharmacokinetic study. After 14 hours' fasting, participants received a single dose of 2x200 mg ibuprofen acid tablets (standard ibuprofen), 2x256 mg ibuprofen sodium dihydrate tablets (sodium ibuprofen; each equivalent to 200 mg ibuprofen acid) and 2x200 mg ibuprofen acid incorporating 60 mg poloxamer 407 (ibuprofen/poloxamer). A washout period of 2-7 days separated consecutive dosing days. On each of the 3 treatment days, blood samples were collected post dose for pharmacokinetic analyses and any adverse events recorded. Plasma concentration of ibuprofen was assessed using a liquid chromatographic-mass spectrometry procedure in negative ion mode. A standard statistical ANOVA model, appropriate for bioequivalence studies, was used and ratios of 90% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%). Ibuprofen/poloxamer was bioequivalent to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than standard ibuprofen (median 75 mins vs 90 mins, respectively; P=0.1913), as the ratio of test/reference=110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and FDA guidelines for bioequivalence. The overall extent of absorption was similar for the three formulations, which were all well tolerated.</p><p><strong>Conclusion: </strong>In terms of Tmax, ibuprofen formulated as a sodium salt was absorbed twice as quickly as from standard ibuprofen acid. The addition of poloxamer to ibuprofen acid did not significantly affect absorption.</p>","PeriodicalId":9196,"journal":{"name":"BMC Clinical Pharmacology","volume":"9 ","pages":"19"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1472-6904-9-19","citationCount":"62","resultStr":"{\"title\":\"Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers.\",\"authors\":\"Peter M Dewland, Sandie Reader, Phillip Berry\",\"doi\":\"10.1186/1472-6904-9-19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of this study was to compare the pharmacokinetic properties of sodium ibuprofen and ibuprofen acid incorporating poloxamer with standard ibuprofen acid tablets.</p><p><strong>Methods: </strong>Twenty-two healthy volunteers were enrolled into this randomised, single-dose, 3-way crossover, open-label, single-centre, pharmacokinetic study. After 14 hours' fasting, participants received a single dose of 2x200 mg ibuprofen acid tablets (standard ibuprofen), 2x256 mg ibuprofen sodium dihydrate tablets (sodium ibuprofen; each equivalent to 200 mg ibuprofen acid) and 2x200 mg ibuprofen acid incorporating 60 mg poloxamer 407 (ibuprofen/poloxamer). A washout period of 2-7 days separated consecutive dosing days. On each of the 3 treatment days, blood samples were collected post dose for pharmacokinetic analyses and any adverse events recorded. Plasma concentration of ibuprofen was assessed using a liquid chromatographic-mass spectrometry procedure in negative ion mode. A standard statistical ANOVA model, appropriate for bioequivalence studies, was used and ratios of 90% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%). Ibuprofen/poloxamer was bioequivalent to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than standard ibuprofen (median 75 mins vs 90 mins, respectively; P=0.1913), as the ratio of test/reference=110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and FDA guidelines for bioequivalence. The overall extent of absorption was similar for the three formulations, which were all well tolerated.</p><p><strong>Conclusion: </strong>In terms of Tmax, ibuprofen formulated as a sodium salt was absorbed twice as quickly as from standard ibuprofen acid. The addition of poloxamer to ibuprofen acid did not significantly affect absorption.</p>\",\"PeriodicalId\":9196,\"journal\":{\"name\":\"BMC Clinical Pharmacology\",\"volume\":\"9 \",\"pages\":\"19\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/1472-6904-9-19\",\"citationCount\":\"62\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Clinical Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1472-6904-9-19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1472-6904-9-19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 62
摘要
背景:本研究的目的是比较布洛芬钠和布洛芬酸加波洛沙姆与标准布洛芬酸片的药动学性质。方法:22名健康志愿者加入了这项随机、单剂量、三向交叉、开放标签、单中心的药代动力学研究。禁食14小时后,参与者接受单剂量2x200mg布洛芬酸片(标准布洛芬),2x256mg布洛芬二水钠片(布洛芬钠;每个相当于200mg布洛芬酸)和2x200mg含60mg poloxam407(布洛芬/ poloxam7)的布洛芬酸。洗脱期为2-7天,间隔连续给药日。在给药后的每一天,采集血液样本进行药代动力学分析,并记录任何不良事件。采用液相色谱-质谱法在负离子模式下评估布洛芬的血浆浓度。采用适用于生物等效性研究的标准统计方差分析模型,并计算90%置信区间(ci)的比值。结果:布洛芬钠的Tmax小于标准布洛芬的一半(中位数分别为35 min和90 min;P=0.0002), Cmax显著高于对照组(41.47 μ g/mL vs 31.88 μ g/mL;试验/参考比值=130.06%,90% CI 118.86-142.32%)。布洛芬/波洛沙姆与标准布洛芬制剂具有生物等效性,尽管其Tmax平均比标准布洛芬短20分钟(中位数分别为75分钟和90分钟;P=0.1913),试验/参比=110.48% (CI 100.96-120.89%),落在CPMP和FDA生物等效性指南80-125%的限定范围内。三种制剂的总体吸收程度相似,均具有良好的耐受性。结论:在Tmax方面,布洛芬钠盐的吸收速度是标准布洛芬酸的两倍。布洛芬酸中加入波洛沙姆对吸收无明显影响。
Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers.
Background: The aim of this study was to compare the pharmacokinetic properties of sodium ibuprofen and ibuprofen acid incorporating poloxamer with standard ibuprofen acid tablets.
Methods: Twenty-two healthy volunteers were enrolled into this randomised, single-dose, 3-way crossover, open-label, single-centre, pharmacokinetic study. After 14 hours' fasting, participants received a single dose of 2x200 mg ibuprofen acid tablets (standard ibuprofen), 2x256 mg ibuprofen sodium dihydrate tablets (sodium ibuprofen; each equivalent to 200 mg ibuprofen acid) and 2x200 mg ibuprofen acid incorporating 60 mg poloxamer 407 (ibuprofen/poloxamer). A washout period of 2-7 days separated consecutive dosing days. On each of the 3 treatment days, blood samples were collected post dose for pharmacokinetic analyses and any adverse events recorded. Plasma concentration of ibuprofen was assessed using a liquid chromatographic-mass spectrometry procedure in negative ion mode. A standard statistical ANOVA model, appropriate for bioequivalence studies, was used and ratios of 90% confidence intervals (CIs) were calculated.
Results: Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%). Ibuprofen/poloxamer was bioequivalent to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than standard ibuprofen (median 75 mins vs 90 mins, respectively; P=0.1913), as the ratio of test/reference=110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and FDA guidelines for bioequivalence. The overall extent of absorption was similar for the three formulations, which were all well tolerated.
Conclusion: In terms of Tmax, ibuprofen formulated as a sodium salt was absorbed twice as quickly as from standard ibuprofen acid. The addition of poloxamer to ibuprofen acid did not significantly affect absorption.